Royalty Pharma plc
RPRX
Clasificación en acciones
#867
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Precio por acción
$62.21
Capitalización bursátil
$27.70B
Cambio (1 día)
3.22%
Cambio (1 año)
69.83%
País
US
Comercio Royalty Pharma plc (RPRX)
Categoría
Healthcare
Ganancias de Royalty Pharma plc (RPRX)
Ganancias en Jun 2026 TTM: $1.35B
Secondo gli ultimi rapporti finanziari di Royalty Pharma plc, gli utili attuali della società sono $1.35B. Nel 2024, la società ha registrato un utile di $1.33B, una disminución en comparación con agli utili del 2023, che erano di $1.70B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Royalty Pharma plc desde 2015 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $1.35B | 1.94% |
| 2025 | $1.32B | -0.50% |
| 2024 | $1.33B | -21.72% |
| 2023 | $1.70B | 638.96% |
| 2022 | $230.06M | -81.46% |
| 2021 | $1.24B | -27.07% |
| 2020 | $1.70B | -30.85% |
| 2019 | $2.46B | 62.16% |
| 2018 | $1.52B | 13.00% |
| 2017 | $1.34B | 76.29% |
| 2016 | $761.90M | 0.42% |
| 2015 | $758.71M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -98.05% |
US
|
|
| $1.21B | -10.73% |
HK
|
